Growth of chronic myeloid leukemia cells is inhibited by infection with Ad-SH2-HA adenovirus that disrupts Grb2-Bcr-Abl complexes

Oncology Reports

Volumn 25, Issue 5, 2011, Pages 1381-1388

  Peng, Zhi ^a   Luo, Hong Wei ^a   Yuan, Ying ^a   Jing, Shi ^a   Huang, Shi Feng ^a   Li, Chun Li ^a   Cao, Wei Xi ^a   Huang, Zong Gan ^a   Feng, Wen Li ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Akt; Bcr Abl; Growth factor receptor bound protein 2; MAPK; Ras; SH2 domain

Indexed keywords

ADENOVIRUS VECTOR; BCR ABL PROTEIN; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; PROTEIN SH2; RAS PROTEIN;

ADENOVIRUS 5; APOPTOSIS; ARTICLE; BINDING AFFINITY; CANCER GENE THERAPY; CANCER INHIBITION; CHRONIC MYELOID LEUKEMIA; COMPLEX FORMATION; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; LEUKEMIA CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; APOPTOSIS; BINDING SITES; CELL LINE, TUMOR; CELL PROLIFERATION; ENZYME ACTIVATION; FUSION PROTEINS, BCR-ABL; GENE ORDER; GENETIC VECTORS; GRB2 ADAPTOR PROTEIN; HEK293 CELLS; HL-60 CELLS; HUMANS; K562 CELLS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; PROTEIN BINDING; PROTEIN TRANSPORT; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS P21(RAS); SRC HOMOLOGY DOMAINS;

EID: 79953055826     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1197     Document Type: Article

References (28)

1. Quintás-Cardama A and Cortes J: Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood 113: 1619-1630, 2009.
2. Baccarani M, Cortes J, Pane F, et al: Chronic myeloid leukemia: an update of concepts and management recommendations of European Leukemia Net. J Clin Oncol 27: 6041-6051, 2009.
3. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN and Sawyers CL: Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293: 876-880, 2001. (Pubitemid 32743979)
4. Kantarjian HM, Giles F, Quintás-Cardama A and Cortes J: Important therapeutic targets in chronic myelogenous leukemia. Clin Cancer Res 13: 1089-1097, 2007. (Pubitemid 46424047)
5. Quintás-Cardama A and Cortes J: Therapeutic options against BCR-ABL1 T315I-positive chronic myelogenous leukemia. Clin Cancer Res 14: 4392-4399, 2008.
6. Million RP and van Etten RA: The Grb2 binding site is required for the induction of chronic myeloid leukemia-like disease in mice by the Bcr/Abl tyrosine kinase. Blood 96: 664-670, 2000. (Pubitemid 30463389)
7. Ren R: Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer 5: 172-183, 2005
8. Chu S, Li L, Singh H and Bhatia R: BCR-tyrosine 177 plays an essential role in Ras and Akt activation and in human hematopoietic progenitor transformation in chronic myelogenous leukemia. Cancer Res 67: 7045-7053, 2007. (Pubitemid 47105554)
9. Check E: Gene therapy: shining hopes dented - but not dashed. Nature 420: 735, 2002.
10. Connolly JB: Lentiviruses in gene therapy clinical research. Gene Ther 9: 1730-1734, 2002.
11. Cornetta K, Morgan RA and Anderson WF: Safety issues related to retroviral-mediated gene transfer in humans. Hum Gene Ther 2: 5-14, 1991. (Pubitemid 121001007)
12. Marshall E: Viral threat to newborns under radar. Science 295: 1631, 2002.
13. Bajocchi G, Feldman SH, Crystal RG and Mastrangeli A: Direct in vivo gene transfer to ependymal cells in the central nervous system using recombinant adenovirus vectors. Nat Genet 3: 229-234, 1993. (Pubitemid 23096558)
14. Neering SJ, Hardy SF, Minamoto D, Spratt SK and Jordan CT: Transduction of primitive human hematopoietic cells with recombinant adenovirus vectors. Blood 88: 1147-1155, 1996. (Pubitemid 26276788)
15. Nilsson M, Ljungberg J, Richter J, et al: Development of an adenoviral vector system with adenovirus serotype 35 tropism; efficient transient gene transfer into primary malignant hematopoietic cells. J Gene Med 6: 631-641, 2004. (Pubitemid 40228079)
16. Pendergast AM, Quilliam LA, Cripe LD, et al: BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell 75: 175-185, 1993. (Pubitemid 23306031)
17. Luo J, Deng ZL, Luo X, et al: A protocol for rapid generation of recombinant adenoviruses using the AdEasy system. Nat Protoc 2: 1236-1247, 2007. (Pubitemid 46908240)
18. Fan X, Brun A and Karlsson S: Adenoviral vector design forhigh level transgene expression in primitive human hemtopoietic progenitors. Gene Ther 7: 2132-2138, 2000. (Pubitemid 32118082)
19. Peng Z, Xiao Z, Wang Y, et al: Reversal of P-glycoprotein-mediated multidrug resistance with small interference RNA (siRNA) in leukemia cells. Cancer Gene Ther 11: 707-712, 2004. (Pubitemid 39488468)
20. Huang SF, Liu DB, Zeng JM, et al: Cloning, expression, purification, distribution and kinetics characterization of the bacterial beta-galactosidase fused to the cytoplasmic transduction peptide in vitro and in vivo. Protein Expr Purif 68: 167-176, 2009.
21. Huang SF, Liu DB, Zeng JM, et al: Cloning, expression, purification and functional characterization of the oligomerization domain of Bcr-Abl oncoprotein fused to the cytoplasmic transduction peptide. Protein Expr Purif 64: 167-178, 2009.
22. + cells. Blood 103: 3167-3174, 2004. (Pubitemid 38451695)
23. Chu S, Li L, Singh H and Bhatia R: BCR-tyrosine 177 plays an essential role in Ras and Akt activation and in human hematopoietic progenitor transformation in chronic myelogenous leukemia. Cancer Res 67: 7045-7053, 2007. (Pubitemid 47105554)
24. Gishizky ML, Cortez D and Pendergast AM: Mutant forms of growth factor-binding protein-2 reverse BCR-ABL-induced transformation. Proc Natl Acad Sci USA 92: 10889-10893, 1995.
25. Kolch W: Coordinating ERK/MAPK signalling through scaffolds and inhibitors. Nat Rev Mol Cell Biol 6: 827-837, 2005.
26. Shaw RJ and Cantley LC: Ras, PI3K and mTOR signalling controls tumour cell growth. Nature 441: 424-430, 2006.
27. Ye YB, Lin JY, Chen Q, et al: The cytotoxicity of a Grb2-SH3 inhibitor in Bcr-Abl positive K562 cells. Biochem Pharmacol 75: 2080-2091, 2008.
28. Kardinal C, Konkol B, Lin H, et al: Chronic myelogenous leukemia blast cell proliferation is inhibited by peptides that disrupt Grb2-SoS complexes. Blood 98: 1773-1781, 2001.